secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0000320017-25-000069
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata reports Q3 2025 net loss $4.2M; cash runway into Q1 2027 with new partnerships
--------------------------------------------------------------------------------

- Net loss $4.2M vs $4.9M in Q3 2024; operating expenses down 17% to $4.4M.
- Cash and equivalents $19.0M; management projects funding operations into Q1 2027.
- ASCEND mPDAC trial final data expected Q1 2026; BOLSTER topline data due Q4 2025.
- Licensed certepetide to Catalent for ADC platform; partnered with GATC Health for AI drug discovery.
- Preliminary CENDIFOX data showed 70% pathologic partial response and 60% 2-year OS in PDAC cohort.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000069/0000320017-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000069/clbs-20251106.htm
  HTML page:      https://secwatch.observer/filing/0000320017-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer